Skip to main content
Equibles
BIOE logo

BIOE · Bio Essence Corp

Track BIOE — free

Use BIOE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BIOE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.42 +0.03 (+7.72%) At close · Oct 19
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company also had an accumulated deficit of $9,077,623 as of June 30, 2026. These conditions raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$22.60M
Shares
53.81M
Volume · Oct 19 5000 Avg daily vol (15 sessions) 16.49K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.42 Open$0.42 Day$0.42–0.42 52W close$0.05–0.52 Avg vol 30d12K Short int2K · 0.0% float · 1.0d Short vol50% DataJul 2024–Oct 2026 Filing10-Q · Aug 14

Up next

Latest filing: 10-Q
filed Aug 14, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$2.91M
Trailing 12 months
Net income (TTM)
$1.52M
Trailing 12 months
Revenue growth YoY
+206.7%
Year over year
Operating margin
52.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$56,161
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+9.5%
Year over year · more shares
Price change (1Y)
+508.7%
Trailing year
Short interest
—
Latest settlement
View all 122 metrics

Quarterly results

Revenue Net income Net loss
▼83.9% $41,695 −$215,678 '24 Q2 ▼13.5% $134,690 −$1.20M '24 Q3 · $22,189 −$205,752 '25 Q1 ▲521.5% $259,123 $59,864 '25 Q2 ▲1.6% $136,800 $12,998 '25 Q3 · $1.48M $1.03M '25 Q4* ▲2155.8% $500,537 $205,373 '26 Q1 LATEST ▲206.7% $794,711 $270,077 '26 Q2

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −21%
below
Price vs 50-day avg +75%
above
RSI (14) 62
neutral
MACD trend Positive
52-week position 79%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +11%
trailing
6-month return +56%
trailing
YTD return +600%
this year
Relative strength +48%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.00% of float · ▼ -52.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Fundamentals
Excellent
Revenue growth +486%
Y/Y
Gross margin 75%
expanding
EPS growth 0%
Y/Y
Free cash flow $1.6M
Quant / Vol
risk profile
Very High
Volatility 402%
annualized · 1-yr
Max drawdown −99%
past year
ATR 11.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−21% Bearish
Price vs 50-day avg
+75% Bullish
RSI (14)
62 Neutral
MACD trend
Positive Bullish
52-week position
79% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.00% of float · ▼ -52.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0 Now $0 · 79% Range high $1
vs 200-day avg -21% vs 50-day avg +75%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BIOE
Bio Essence Corp
this stock
$22.60M +600.2% +485.8% — 0.0%
TAK
Takeda Pharmaceutical Co Ltd
 $64.15B +27.8% — — 0.1%
GALDY
Galderma Group AG
 $48.88B +2.4% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $46.21B +30.2% +4.3% 65.0 2.6%
HLN
Haleon plc
 $44.72B -0.9% — — 0.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest Falling
Shares short
2.5K
Days to cover
1.0d
Change
-2.8K sh
View
Short Volume
Short vol %
50%
As of
Oct 19, 2026
Short Total
View
Fails to Deliver
FTD shares
11.5K
Value
$5.8K
As of
Oct 31, 2024
View
Off-Exchange
Off-exchange %
100.0%
Week of
Sep 7, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$1.9M
Net income (FY)
$896.2K
EPS diluted
$-0.03
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 14, 2026
This year
5
View
Proposed Sales
Value
$148.5K
Shares
550.0K
Filed
Oct 13, 2026
View

Performance

5D 20D 120D MTD YTD
BIOE +57.3% +10.6% +55.6% +130.8% +600.2%
SPY -1.5% -0.9% +7.7% +0.5% +12.4%
vs SPY +58.8% +11.5% +47.9% +130.3% +587.8%
Key facts CIK 1723059 Visit website